Progress on the effects of tyrosine kinase inhibitors on the growth and development of children with chronic myeloid leukemia
10.3760/cma.j.issn.1673-4408.2023.09.006
- VernacularTitle:酪氨酸激酶抑制剂对慢性粒细胞白血病儿童生长发育影响的研究进展
- Author:
Fangyuan ZHENG
1
;
Leping ZHANG
Author Information
1. 北京大学人民医院儿科 100044
- Keywords:
Children;
Tyrosine kinase inhibitors;
Chronic myeloid leukemia;
Growth and development
- From:
International Journal of Pediatrics
2023;50(9):600-603
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor(TKI), the first-line treatment for chronic myeloid leukemia(CML), can achieve long-term survival for CML patients.For TKI therapy in children with CML, the pediatricians should not only consider the same adverse reactions as adults, but also pay attention to its impact on children′s height and gonads.At present, multiple studies abroad have found that the use of imatinib can delay the growth and development of children with CML.However, the experience of dasatinib and nilotinib in children with CML is still lacking, and there are few relevant research reports, and their impact on the growth and development of children is still unclear.This article reviews the research progress on the mechanism, clinical research data, and treatment of growth and development disturbances of children with CML treated with TKIs.
